tbuckley/cabot-search huggingface dataset:
Successful cold polypectomy for ectopic endometriosis in a narrow distal bile duct using a new slim cholangioscope
Authors: Hirotsugu Maruyama, Yuki Ishikawa-Kakiya, Yuji Kawata, Tatsuya Kurokawa, Yoshinori Shimamoto, Kojiro Tanoue, Yasuhiro Fujiwara
Journal: Endoscopy (2025)
Identification of 1 mm of preserved muscularis propria on MRI accurately identifies early rectal cancers suitable for local excision in the intermuscular plane
Authors: Lisa van der Schee, Rachel Carten, Sander C. Albers, Janneke van den Bergh, Manon N.G.J.A. Braat, Arnold C. Goede, Sabrine Kol, M.M Lacle, Banafsche Mearadji, Shira I. Moos, Irene M. Nota, Nicky H.G.M. Peters, Jip F. Prince, Jorik J. Reimerink, Arantza Fariña Sarasqueta, Jeanette van Vooren, Jan Hein T.M. van Waesberghe, Barbara A.J. Bastiaansen, Frank P. Vleggaar, Leon MG Moons, Karin Horsthuis, Gina Brown
Journal: Endoscopy (2025)

Background and Study Aims: Selection of rectal cancer cases suitable for endoscopic intermuscular dissection (EID) is challenging. We aimed to evaluate whether identification of ≥ 1mm of preserved muscularis propria on MRI, using a systematic MRI reporting tool (mrSRT), can identify rectal cancers suitable for EID. Patients and methods: Twelve radiologists underwent training in the mrSRT by an expert radiologist. The radiologists then assessed a retrospective case series of MRIs from 269 consecutive patients with suspected deep submucosal invasive rectal cancer. The primary objective was to determine the diagnostic accuracy of preservation of ≥1mm of muscularis propria on MRI for selecting cases that can be resected with clear margins using EID (invasion limited to the circular muscularis propria (≤pT2circ)). Diagnostic accuracy was calculated for the expert radiologist, study radiologists, and a consensus diagnosis. Results: After applying the inclusion and exclusion criteria, a total of 244 patient scans were included in the analysis. Histological classification confirmed 18 (7%) lesions were non-invasive, 109 (45%) were pT1, 56 (23%) were pT2circ , 21 (9%) were pT2long, 39 (16%) were pT3, and 1 (0.4%) was pT4. The overall diagnostic accuracy of the ≥ 1 mm of preserved muscularis propria criterion was 81% (95%CI 75-85) for the expert radiologist diagnosis, 77% (95%CI 72-83) for the trained study radiologists, and 82% (95%CI 76-86) for a consensus diagnosis. Conclusion: Use of mrSRT to identify ≥1mm of preserved muscularis propria on MRI allows radiologists to assist in appropriate case selection for EID.
Clinical and financial implications of inpatient and outpatient management of worsening heart failure
Authors: Stephen J. Greene, Lisa A. Kaltenbach, Gregg C. Fonarow, Karen Chiswell, Veraprapas Kittipibul, Hubert B. Haywood, Muhammad Shahzeb Khan, Bradley G. Hammill, Javed Butler, Adrian F. Hernandez, G. Michael Felker
Journal: European Journal of Heart Failure (2025)
CD44-targeted RIP3 gene delivery strategy for enhanced cancer therapy via necroptosis and immune modulation
Authors: Sang Eun Kim, Soyeon Bak, Jung Hee Park, Ji Eun Lee, Yun Ji Lee, Min Seok Park, Soyeon Ko, Hani Choi, Kyung Hee Jung, Kun Na, Soon-Sun Hong
Journal: Journal of Controlled Release (2025)
Multicentre evaluation of deep learning CT autosegmentation of the head and neck region for radiotherapy
Authors: Eric Pei Ping Pang, Hong Qi Tan, Fuqiang Wang, Jarkko Niemelä, Gregory Bolard, Susan Ramadan, Timo Kiljunen, Marta Capala, Steven Petit, Jan Seppälä, Kristiina Vuolukka, Ingrid Kiitam, Danil Zolotuhhin, Eduard Gershkevitsh, Kaisa Lehtiö, Juha Nikkinen, Jani Keyriläinen, Miia Mokka, Melvin Lee Kiang Chua
Journal: npj Digital Medicine (2025)

This is a multi-institutional study to evaluate a head-and-neck CT auto-segmentation software across seven institutions globally. 11 lymph node levels and 7 organs-at-risk contours were evaluated in a two-phase study design. Time savings were measured in both phases, and the inter-observer variability across the seven institutions was quantified in phase two. Overall time savings were found to be 42% in phase one and 49% in phase two. Lymph node levels IA, IB, III, IVA, and IVB showed no significant time savings, with some centers reporting longer editing times than manual delineation. All the edited ROIs showed reduced inter-observer variability compared to manual segmentation. Our study shows that auto-segmentation plays a crucial role in harmonizing contouring practices globally. However, the clinical benefits of auto-segmentation software vary significantly across ROIs and between clinics. To maximize its potential, institution-specific commissioning is required to optimize the clinical benefits.
Adverse Events After Surveillance Colonoscopy in Older Adults In A Large Integrated Health System in the United States.
Authors: Jeffrey K. Lee, Christopher D. Jensen, Sophie A. Merchant, Jessica Chubak, Ethan A. Halm, Douglas A. Corley, Joanne E. Schottinger, Celette Sugg Skinner
Journal: Clinical Gastroenterology and Hepatology (2025)
Effectiveness of virtual reality interventions on quality of life, cognitive function and physical function in older people with Alzheimer's disease: A systematic review
Authors: Edgar Vásquez-Carrasco, Jordan Hernandez-Martinez, María Sepúlveda-Ramírez, Florencia Carmine, Cristian Sandoval, Hadi Nobari, Pablo Valdés-Badilla
Journal: Ageing Research Reviews (2025)
Ingestion of mast cell granules boosts macrophages and drives atypical programming
Authors: Konstantinos Katsoulis-Dimitriou, Julia Schmidt, Marc Roder, Jan Dudeck, Lars Philipsen, James P. Koch, Maria Cattelan, Lea Schmitter, Olga Biskou, Aaron Hoffmann, Michael Mihlan, Rohit Sharma, Johanna Kotrba, Martin Voss, Mahsa Abedi, Ina Sauerland, Stefan Frischbutter, Christina E. Zielinski, Robert Geffers, Tim Lämmermann, Andreas J. Müller, Sascha Kahlfuß, Anne Dudeck
Journal: Journal of Allergy and Clinical Immunology (2025)
From distance to resonance: A qualitative study on overcoming countertransferential anxieties in therapy with transgender and nonbinary patients
Authors: G. Giovanardi, M. Mirabella, G. Protopapa, B. Di Giannantonio, N. Carone, M. P. Casini, V. Lingiardi, A. M. Speranza, A. Fortunato
Journal: International Journal of Transgender Health (2025)
Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and/or Immune Checkpoint Inhibitor Therapy: A Multicenter Analysis
Authors: Daniel S Roberson, Vidit Sharma, Stephen A Boorjian, Matthew T McLeay, Giuseppe Reitano, Mimi V Nguyen, Jacob J Orme, Daniel S Childs, Lance C Pagliaro, Aaron M Potretzke, R Jeffrey Karnes, Paras Shah, Andrew Zganjar, Timothy Lyon, Mark D Tyson, Abhinav Khanna
Journal: European Urology (2025)
Panoramic spatial enhanced resolution proteomics (PSERP) reveals tumor architecture and heterogeneity in gliomas
Authors: Ziyan Xu, Yunzhi Wang, Tao Xie, Rongkui Luo, Heng-Li Ni, Hang Xiang, Shaoshuai Tang, Subei Tan, Rundong Fang, Peng Ran, Qiao Zhang, Xiaomeng Xu, Sha Tian, Fuchu He, Wenjun Yang, Chen Ding
Journal: Journal of Hematology & Oncology (2025)

The spatial proteomic profiling of complex tissues is essential for investigating cellular function in physiological and pathological states. However, the imbalance among resolution, protein coverage, and expense precludes their systematic application to analyze whole tissue sections in an unbiased manner and with high resolution. Here, we introduce panoramic spatial enhanced resolution proteomics (PSERP), a method that combines tissue expansion, automated sample segmentation, and tryptic digestion with high-throughput proteomic profiling. The PSERP approach facilitates rapid quantitative profiling of proteomic spatial variability in whole tissue sections at sub-millimeter resolution. We demonstrated the utility of this method for determining the streamlined large-scale spatial proteomic features of gliomas. Specifically, we profiled spatial proteomic features for nine glioma samples across three different mutation types (IDH1-WT/EGFR-mutant, IDH1-mutant, and IDH1/EGFR-double-WT gliomas) at sub-millimeter resolution (corresponding to a total of 2,230 voxels). The results revealed over 10,000 proteins identified in a single slide, which helps us to portray the diverse proteins and pathways with spatial abundance patterns in the context of tumor heterogeneity and cellular features. Our spatial proteomic data revealed distinctive proteomic features of malignant and non-malignant tumor regions and depicted the distribution of proteins from tumor centers to tumor borders and non-malignant tumor regions. Through integrative analysis with single-cell transcriptomic data, we elucidated the cellular composition and cell-cell communications in a spatial context. Our PSERP also includes a spatially resolved tumor-specific peptidome identification workflow that not only enables us to elucidate the spatial expression patterns of tumor-specific peptides in glioma samples with different genomic types but also provides us with opportunities to select combinations of tumor-specific mutational peptides whose expression could cover the maximum tumor regions for future immune therapies. We further demonstrated that combining tumor-specific peptides might enhance the efficacy of immunotherapy in both patient-derived cell (PDC) and patient-derived xenograft (PDX) models. PSERP efficiently retains precise spatial proteomic information within the tissue context and provides a deeper understanding of tissue biology and pathology at the molecular level.
Lipoprotein(a), Cholesterol, Triglyceride Levels, and Vulnerable Coronary Plaques
Authors: David Erlinge, Sotirios Tsimikas, Michael Maeng, Akiko Maehara, Alf Inge Larsen, Thomas Engstrøm, Lars Kjøller-Hansen, Mitsuaki Matsumura, Ori Ben-Yehuda, Hans Erik Bøtker, Ole Fröbert, Jonas Persson, Rune Wiseth, Lisette O. Jensen, Jan E. Nordrehaug, Thor Trovik, Ulf Jensen, Øyvind Bleie, Elmir Omerovic, Stefan K. James, Rebecca Rylance, Tania Sharma, Ziad A. Ali, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2025)
Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies
Authors: Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Panagiotis Malandrakis, Efstathios Kastritis, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Maria Gavriatopoulou
Journal: Blood Cancer Journal (2025)

While observation is the current standard of care for smoldering multiple myeloma (sMM), emerging evidence suggests that early therapeutic intervention may delay progression and improve outcomes especially for high-risk patients. A systematic review and meta-analysis of randomized clinical trials was performed according to the PRISMA guidelines in order to evaluate the effect of treatment compared to observation in outcomes of patients with sMM. Five studies (7 articles) involving 844 patients with intermediate or high risk sMM and comparing treatment to observation or placebo were deemed eligible. All studies reported progression-free survival results, with progression defined as time to active myeloma (without high heterogeneity, I2 = 42%, p = 0.14). A statistically significant 60% reduced pooled risk for disease progression or death (HR = 0.40, 95%CI:0.29-0.55) was revealed for patients who underwent treatment compared to those who did not. An exploratory sensitivity analysis involving 3 trials with only observation in the control group, revealed a 66% lower risk for disease progression or death (HR = 0.34, 95%CI: 0.21-0.56) for patients in the treatment group compared to the control group. Furthermore, time-to-progression was reported in 3 studies; the pooled effect estimate revealed a statistically significant 58% reduced risk for progression to symptomatic MM (HR = 0.42, 95%CI: 0.29-0.61) for patients who underwent treatment compared to those who did not. Only 2 trials reported mature overall survival outcomes, and the pooled effect estimate showed a 45% lower risk for death (HR = 0.55, 95%CI: 0.37-0.82) for sMM patients who received treatment compared to those on observation. Regarding safety, the odds for serious adverse events for those on treatment was as 3.5 times as high (OR = 3.53, 95%CI: 1.14-10.91) compared to those on observation or placebo. In conclusion, this meta-analysis highlights the significant benefits of early treatment in selected patients with sMM, across key clinical outcomes. However, close monitoring is essential for the management of treatment-related toxicities.
The effect of bivalent HPV vaccination against invasive cervical cancer and cervical intraepithelial neoplasia grade 3 (CIN3+) in the Netherlands: a population-based linkage study
Authors: Marit Middeldorp, Jesca G.M. Brouwer, Janneke W. Duijster, Mirjam J. Knol, Folkert J. van Kemenade, Albert G. Siebers, Johannes Berkhof, Hester E. de Melker
Journal: The Lancet Regional Health - Europe (2025)
Imaging poly(ADP-ribose) polymerase-1 (PARP1) in vivo with 18F-labeled brain penetrant positron emission tomography (PET) ligand
Authors: Xin Zhou, Jiahui Chen, Jimmy S. Patel, Wenqing Ran, Yinlong Li, Richard S. Van, Mostafa M.H. Ibrahim, Chunyu Zhao, Yabiao Gao, Jian Rong, Ahmad F. Chaudhary, Guocong Li, Junqi Hu, April T. Davenport, James B. Daunais, Yihan Shao, Chongzhao Ran, Thomas L. Collier, Ahmed Haider, David M. Schuster, Allan Levey, Lu Wang, Gabriel Corfas, Steven H. Liang
Journal: Acta Pharmaceutica Sinica B (2025)
RXRα modulates hepatic stellate cell activation and liver fibrosis by targeting CaMKKβ–AMPKα axis
Authors: Lijun Cai, Meimei Yin, Shuangzhou Peng, Fen Lin, Liangliang Lai, Xindao Zhang, Lei Xie, Chuanying Wang, Huiying Zhou, Yunfeng Zhan, Gulimiran Alitongbieke, Baohuan Lian, Zhibin Su, Tenghui Liu, Yuqi Zhou, Zongxi Li, Xiaohui Chen, Qi Zhao, Ting Deng, Lulu Chen, Jingwei Su, Luoyan Sheng, Ying Su, Ling-juan Zhang, Fu-Quan Jiang, Xiao-Kun Zhang
Journal: Acta Pharmaceutica Sinica B (2025)
Alternative Splicing in Mechanically Stretched Podocytes as a Model of Glomerular Hypertension
Authors: Francescapaola Mattias, Olga Tsoy, Elke Hammer, Alexander Gress, Stefan Simm, Chit Tong Lio, Sabine Ameling, Kerstin Amann, Leonie Dreher, Ulrich Wenzel, Tim Kacprowski, Markus List, Olga Kalinina, Karlhans Endlich, Jan Baumbach, Uwe Völker, Nicole Endlich, Felix Kliewe
Journal: Journal of the American Society of Nephrology (2025)

Background: Alterations in pre-mRNA splicing are crucial to the pathophysiology of various diseases. However, the effects of alternative splicing of mRNA on podocytes in hypertensive nephropathy are still unknown. The Sys_CARE project aimed to identify alternative splicing events involved in the development and progression of glomerular hypertension. Methods: Murine podocytes were exposed to mechanical stretch, after which proteins and mRNA were analyzed by proteomics, RNA sequencing and several bioinformatic alternative splicing tools. Results: Using transcriptomic and proteomic analysis, we identified significant changes in gene expression and protein abundance due to mechanical stretch. RNA-Seq identified over 3,000 alternative spliced genes after mechanical stretch, including all types of alternative splicing events. Among these, 17 genes exhibited an alternative splicing event across four different splicing analysis tools. From this group, we focused on Myl6 , a component of the myosin protein complex, and Shroom3 , an actin-binding protein essential for podocyte function. We identified two Shroom3 isoforms with significant expression changes under mechanical stretch, which was validated by qRT-PCR and in situ hybridization. Additionally, we observed an expression switch of two Myl6 isoforms after mechanical stretch, accompanied by an alteration in the C-terminal amino acid sequence. Conclusions: A comprehensive RNA-Seq analysis of mechanically stretched podocytes identified novel potential podocyte-specific biomarkers and highlighted significant alternative splicing events, notably in the mRNA of Shroom3 and Myl6.
Camrelizumab combined with Lenvatinib and RALOX-HAIC for unresectable hepatocellular carcinoma (Cal Era): a prospective, single-arm, phase II trial
Authors: Mengya Zang, Qi Li, Xiaoyun Hu, Huajin Pang, Rong Li, Wenli Li, Yongru Chen, Peilin Zhu, Kaiyan Su, Guosheng Yuan, Yuan Li, Yuanfeng Li, Jinzhang Chen
Journal: Liver Cancer (2025)

Introduction: Combining systemic agents with hepatic arterial infusion chemotherapy (HAIC) has produced promising outcomes in advanced hepatocellular carcinoma (HCC). Raltitrexed, an antimetabolite recognized for its extended plasma half-life, enables shorter infusion schedules. This study aimed to assess the efficacy, safety, and potential predictive biomarkers of a therapeutic approach incorporating camrelizumab, lenvatinib, and a HAIC protocol using raltitrexed plus oxaliplatin (RALOX) in patients with intermediate to advanced HCC. Methods: Participants in this single-arm phase II study (NCT05003700) had Barcelona Clinic Liver Cancer (BCLC) stage B or C HCC. They received RALOX-HAIC in tandem with camrelizumab and lenvatinib for a maximum of six cycles, continuing until either disease progression or unacceptable toxicity. The primary outcome measure was the objective response rate (ORR). Results: Thirty-nine individuals underwent at least one tumor review after baseline. The confirmed ORR was 66.7% (95% CI, 49.8–80.9). The median progression-free survival was 13.8 months (95% CI, 10.5–20.5), and the median overall survival was 21.2 months (95% CI, 14.3–21.2). Grade 3-4 treatment-related adverse events occurred in 79.5% of the subjects, with the most common being decreased neutrophil count (41%), decreased platelet count (30.8%), and increased aspartate aminotransferase (23.1%). All side effects were, as anticipated, controllable, and no treatment-related deaths were reported. Serum IL2, CXCL13, and CCL19 levels significantly differed between stable disease and partial response patients (P &lt; 0.05 and |fold change| &gt; 1.5). Furthermore, risk stratification based on these three biomarkers revealed shorter progression-free survival and overall survival in high-risk versus low-risk subgroups (P &lt; 0.05). These results suggested that the serum concentrations of IL-2, CXCL13, and CCL19 emerged as potential predictors of clinical benefits under this triple-combination protocol. Conclusion: The triple regimen of camrelizumab, lenvatinib, and RALOX-HAIC exhibited notable antitumor capabilities and acceptable tolerability in patients with advanced HCC. Moreover, baseline levels of IL-2, CXCL13, and CCL19 may function as predictive indicators of the response to this first-line therapeutic strategy.
Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab.
Authors: Bernardo Stefanini, Fabio Piscaglia, Fabio Marra, Massimo Iavarone, Caterina Vivaldi, Giuseppe Cabibbo, Andrea Palloni, Tiziana Pressiani, Andrea Dalbeni, Benedetta Stefanini, Leonardo Stella, Piera Federico, Gianluca Svegliati-Baroni, Sara Lonardi, Caterina Soldà, Luca Ielasi, Stefania De Lorenzo, Ingrid Garajova, Claudia Campani, Mariangela Bruccoleri, Gianluca Masi, Ciro Celsa, Giovanni Brandi, Alessandra Auriemma, Bruno Daniele, Francesca Romana Ponziani, Lorenzo Lani, Rusi Chen, Maria Boe, Alessandro Granito, Lorenza Rimassa, Francesco Tovoli
Journal: Liver Cancer (2025)

Background: Preclinical models have shown that metabolic dysfunction-associated steatotic liver disease (MASLD)-related hepatocellular carcinoma (HCC) may exhibit reduced responsiveness to immunotherapy, especially for intrahepatic lesions due to liver tumour microenvironment. Radiological pattern of progression has been validated in clinical studies as a useful tool for predicting outcomes in HCC undergoing systemic treatments. Aims. To determine whether MASLD influences the pattern of progression in patients treated with atezolizumab-bevacizumab. Methods: This multicenter, prospective study included patients with unresectable HCC receiving atezolizumab-bevacizumab. Progression patterns were defined as previously proposed. Patients were categorized as either MASLD or controls based on a recent multisocietal Delphi consensus statement. Multivariable models analyzed the risk of specific progression patterns and their impacts on post-progression survival (PPS) and overall survival (OS). A historical cohort treated with sorafenib was also analyzed to determine whether observed patterns were specific for atezolizumab-bevacizumab. Results: Four-hundred-twenty patients were included (MASLD: n=88, 21.0%). Time-to-progression (TTP) was shorter in MASLD compared to controls, due to an increased risk of intrahepatic growth [IHG – hazard ratio (HR) 1.739, 95% confidence interval (CI) 1.206-2.507, p=0.003)]. Neither etiology nor IHG predicted a different PPS. No differences between etiologies were found in OS. Etiology did not influence the pattern of progression under sorafenib in the historical cohort. Conclusion: IHG was more frequently associated with MASLD-HCC compared to controls, confirming preclinical data and suggesting biological differences between tumors, with potential implications for future research. MASLD should not be seen as a contraindication to immunotherapy.
Zinc-mediated metalloimmunotherapy with dual elimination of tumor and intratumoral bacteria in oral squamous cell carcinoma
Authors: Jia-Ying Zhou, Qing-Hua Shen, Yu-Wen Xiong, Jia-Wen Chen, Qi Hui, Rui Zhou, Yi-Fei Luo, Bin Cheng, Cai-Ping Tan, Tong Wu
Journal: Biomaterials (2025)
Multifunctional nanocomposite hydrogel with dual-factor controlled release for stem cell recruitment, immunomodulation and bone remodeling
Authors: Yang Jiao, Haixin Wang, Mingyu Zhao, Huiling Liu, Peng Shen, Gang Wu, Tim Forouzanfar, Franklin R. Tay, Li Miao, Hongchen Liu, Qian Liu
Journal: Journal of Controlled Release (2025)
Type 2 cytokines pleiotropically modulate sensory nerve architecture and neuroimmune interactions to mediate itch
Authors: Mithilesh Kumar Jha, Yingnan Han, Zhipeng Liu, Yannis Hara, Ingeborg M. Langohr, Caroline Morel, Colleen Maloney, Peter Piepenhagen, Heming Xing, Corneliu A. Bodea, Dinesh S. Bangari, Hamid Mattoo, Alexandra Hicks
Journal: Journal of Allergy and Clinical Immunology (2025)
CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models
Authors: Kai Shang, Deyu Huang, Jun Liu, Zebin Yu, Wei Bian, Jiangqing Chen, Yin Zhao, Lina Liu, Jie Jiang, Yajie Wang, Yanting Duan, Jingyu Ge, Shize Zhang, Chun Zhou, Yingli Han, Yongxian Hu, Weiyan Zheng, Jie Sun, He Huang, Shanshan Pei, Pengxu Qian, Jie Sun
Journal: Cell Reports Medicine (2025)
Enhancer-driven gene regulatory networks reveal transcription factors governing T cell adaptation and differentiation in the tumor microenvironment
Authors: William D Green, Amber Gomez, Alec L Plotkin, Brandon M Pratt, Emily F Merritt, Genevieve N Mullins, Nancy P Kren, Jennifer L Modliszewski, Vasyl Zhabotynsky, Mark G Woodcock, Jarred M Green, Gabrielle Cannon, Matthew E Pipkin, Gianpietro Dotti, Jessica E Thaxton, Yuliya Pylayeva-Gupta, Albert S Baldwin, John P Morris, Natalie Stanley, J Justin Milner
Journal: Immunity (2025)